Cargando…
Obesity and contraceptive use: impact on cardiovascular risk
Obesity and oestrogen containing contraceptive products are well‐known independent cardiovascular risk factors. However, a significant number of obese women continue to receive prescriptions of hormonal products that contain oestrogens for their contraception. We have conducted a narrative review to...
Autores principales: | Rosano, Giuseppe M.C., Rodriguez‐Martinez, Maria Angeles, Spoletini, Ilaria, Regidor, Pedro Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773763/ https://www.ncbi.nlm.nih.gov/pubmed/36103980 http://dx.doi.org/10.1002/ehf2.14104 |
Ejemplares similares
-
Correction to: “Obesity and contraceptive use: impact on cardiovascular risk”
Publicado: (2023) -
The clinical relevance of progestogens in hormonal contraception: Present status and future developments
por: Regidor, Pedro-Antonio
Publicado: (2018) -
Monitoring functional capacity in heart failure
por: Piepoli, Massimo F, et al.
Publicado: (2019) -
Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime
por: Palacios, Santiago, et al.
Publicado: (2020) -
Hyperkalemia and Renin–Angiotensin–Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction
por: Rosano, Giuseppe MC, et al.
Publicado: (2019)